865712-83-0

Basic information

• Product Name: 1-cyclohexyl-methyl-7-methoxy-3-oxazol-2-yl-1H-indole
• Synonyms: 1-cyclohexyl-methyl-7-methoxy-3-oxazol-2-yl-1H-indole
• CAS NO: 865712-83-0
• Molecular Weight: 310.396
• Mol File: 865712-83-0.mol

Chemical Properties

• CAS DataBase Reference: 1-cyclohexyl-methyl-7-methoxy-3-oxazol-2-yl-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyclohexyl-methyl-7-methoxy-3-oxazol-2-yl-1H-indole(865712-83-0)
• EPA Substance Registry System: 1-cyclohexyl-methyl-7-methoxy-3-oxazol-2-yl-1H-indole(865712-83-0)

Safety Data

• Hazardous Substances Data: 865712-83-0(Hazardous Substances Data)

Upstream product

• 20656-61-5 methyl 2-chloro-3-oxopropionate 
• 865712-37-4 1-(cyclohexyl)methyl-7-methoxy-1H-indole-3-carboxylic acid amide 

Downstream Products

• 865712-84-1 [2-(1-cyclohexylmethyl-7-methoxy-1H-indol-3-yl)-oxazol-5-yl]-methanol 

Relevant articles and documents

(INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR

The invention relates to (indol-3-yl)-heterocycle derivatives having general Formula (I) wherein A represents a 5-membered aromatic heterocyclic ring, wherein X1, X2 and X3 are independently selected from N, O, S and CR; R is H or (C1-4)alkyl; or R, when present in X2 or X3, may form together with R3 a 5-8 membered ring; R1 is a 5-8 mem-bered saturated carbocyclic ring, optionally containing a heteroatom selected from O and S; R2 is H, CH3 or CH2-CH3;or R2 is joined together with R7 to form a 6-mem-bered ring, optionally containing a heteroatom selected from O and S, and which heteroatom is bonded to the 7-position of the indole ring; R3 and R4 are independent-ly H, (C1-6)alkyl or (C3-7)cycloalkyl, the alkyl groups being optionally substituted with OH, (C1-4)alkyloxy, (C1-4)alkylthio, (C1-4)alkylsulfonyl, CN or halogen; or R3 together with R4 and the N to which they are bonded form a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally sub-stituted with OH, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy- (C1-4)alkyl, or halogen; or R3 together with R5 forms a 4-8 membered ring optionally containing a further hetero-atom selected from O and S, and which is optionally substituted with OH, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy- (C1-4)alkyl, or halogen; or R3 together with R, when present in X2 or X3, forms a 5-8 membered ring; R5 is H or (C1-4)alkyl; or R5 together with R3 forms a 4-8 membered ring optionally containing a further heteroatom select-ed from O and S, and which is optionally substituted with OH, (C1-4)alkyl, (C1-4)alkyl-oxy, (C1-4) alkyloxy- (C1-4)alkyl, or halogen; R5' is H or (C1-4)alkyl; R6 represents 1-3 substituents independently selected from H, (C1-4 alkyl, (C1-4) alkyloxy, CN and halogen; R7 is H, (C1-4)alkyl, (C1-4)alkyloxy, CN or halogen; or R7 is joined together with R2 to form a 6-membered ring, optionally containing a further heteroatom selected from O and S, and which heteroatom is bonded to the 7-position of the indole ring; or a pharmaceutically acceptable salt thereof, as agonists of the cannabinoid CB1 receptor, which can be used in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.